Psyence Biomedical Ltd. Warrant
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for … Read more
Psyence Biomedical Ltd. Warrant (PBMWW) - Net Assets
Latest net assets as of September 2025: $11.87 Million USD
Based on the latest financial reports, Psyence Biomedical Ltd. Warrant (PBMWW) has net assets worth $11.87 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($12.81 Million) and total liabilities ($943.07K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $11.87 Million |
| % of Total Assets | 92.64% |
| Annual Growth Rate | 8.78% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 2332.52 |
Psyence Biomedical Ltd. Warrant - Net Assets Trend (2021–2025)
This chart illustrates how Psyence Biomedical Ltd. Warrant's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Psyence Biomedical Ltd. Warrant (2021–2025)
The table below shows the annual net assets of Psyence Biomedical Ltd. Warrant from 2021 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $6.72 Million | +161.26% |
| 2024-03-31 | $-10.97 Million | -104.48% |
| 2023-03-31 | $244.66 Million | +2.01% |
| 2022-03-31 | $239.84 Million | +4895.92% |
| 2021-03-31 | $4.80 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Psyence Biomedical Ltd. Warrant's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5644720400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $61.75 Million | 918.66% |
| Other Comprehensive Income | $351.20K | 5.22% |
| Other Components | $1.07 Million | 15.85% |
| Total Equity | $6.72 Million | 100.00% |
Psyence Biomedical Ltd. Warrant Competitors by Market Cap
The table below lists competitors of Psyence Biomedical Ltd. Warrant ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Fat Prophets Global Property Fund
AU:FPP
|
$5.39K |
|
Agritek Holdings Inc
PINK:AGTK
|
$5.39K |
|
TFBS Bioscience Inc.
TWO:6939
|
$5.40K |
|
KENYA ORCHARDS LTD
XNAI:KOL
|
$5.40K |
|
UET UTD ELECTR - Dusseldorf Stock Exchang
DU:CFC
|
$5.38K |
|
Kooth plc
LSE:KOO
|
$5.37K |
|
GTC (G91.SG)
STU:G91
|
$5.36K |
|
Organic Garage Ltd
PINK:OGGFF
|
$5.35K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Psyence Biomedical Ltd. Warrant's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -10,972,540 to 6,722,004, a change of 17,694,544.
- Net income of 1,011,790 contributed positively to equity growth.
- New share issuances of 1,742,051 increased equity.
- Other comprehensive income decreased equity by 9,859.
- Other factors increased equity by 14,950,562.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $1.01 Million | +15.05% |
| Share Issuances | $1.74 Million | +25.92% |
| Other Comprehensive Income | $-9.86K | -0.15% |
| Other Changes | $14.95 Million | +222.41% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Psyence Biomedical Ltd. Warrant's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-03-31 | $0.38 | $0.02 | x |
| 2022-03-31 | $7.24 | $0.02 | x |
| 2023-03-31 | $7.49 | $0.02 | x |
| 2024-03-31 | $-1.68 | $0.02 | x |
| 2025-03-31 | $11.83 | $0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Psyence Biomedical Ltd. Warrant utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.05%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.09x
- Recent ROE (15.05%) is above the historical average (5.45%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 3.48% | 0.00% | 0.00x | 1.08x | $-15.43 Million |
| 2023 | 3.28% | 0.00% | 0.00x | 1.06x | $-16.45 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-50.06 Million |
| 2025 | 15.05% | 0.00% | 0.00x | 1.09x | $339.59K |
Industry Comparison
This section compares Psyence Biomedical Ltd. Warrant's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Psyence Biomedical Ltd. Warrant (PBMWW) | $11.87 Million | 3.48% | 0.08x | $5.39K |
| Abcam plc (ABCZF) | $726.90 Million | -1.17% | 0.45x | $5.00 Billion |
| Able View Global Inc. Warrant (ABLVW) | $11.42 Million | 85.41% | 3.81x | $277.93K |
| Above Food Ingredients Inc. Warrants (ABVEW) | $199.86 Million | -2.89% | 0.00x | $6.25 Million |
| Adamas Trust, Inc. (ADAMG) | $2.43 Billion | 7.94% | 1.33x | $2.09 Billion |
| ADS-TEC ENERGY PLC Warrant (ADSEW) | $33.92 Million | -162.39% | 2.67x | $10.06 Million |
| Alliance Entertainment Holding Corporation Warrants (AENTW) | $52.92 Million | 10.13% | 4.23x | $2.29 Million |
| Forafric Global PLC Warrants (AFRIW) | $5.32 Million | -457.58% | 45.29x | $2.67 Million |
| Centurion Acquisition Corp. Warrant (ALFUW) | $282.84 Million | 1.97% | 0.05x | $4.81 Million |
| Alliance Trust PLC (ALITF) | $4.04 Billion | 10.04% | 0.29x | $112.87K |
| Alvotech Warrant (ALVOW) | $-564.42 Million | 0.00% | 0.00x | $35.01 Million |